
Nelli lives with chronic pain. It took her 20 years to find the right help
"There is only so much they can do for me surgically. So, I manage my pain on a day-to-day basis through a number of physical interventions, as well as medical interventions as well."
Stevenson works for a community legal service with flexible arrangements, and says she is fortunate to have access to a specialist GP and team who support her physical therapy and pain management. "However, it took me about 20 years of pushing through the medical system, constantly advocating for myself and fighting to be taken seriously, to be able to find that group of people," she said. This started in her late teens. "I was told, like most people with pelvic pain, that it's just part of being a woman, it's part of your period. I was gaslit for several years," she said. This had serious consequences. At one point, Stevenson says she had normalised the chronic abdominal pain she was experiencing that she didn't notice her appendix had ruptured. "I didn't present to hospital until 12 days after it had happened," she said. Stevenson ended up in ICU and needed two major surgeries to save her life. She says these caused significant scar tissue, which added to her chronic pain.
She said she has heard many stories of late diagnosis, misdiagnosis and gaslighting from the chronic pain community.
"They [medical professionals] aren't taking seriously these people who are saying, 'I cannot live like this anymore. I need more help.'" Chronic pain is taking longer to diagnose in 2025, according to a new report from peak consumer body Chronic Pain Australia .
The 11th edition of its National Pain Survey, released on Monday to kick off a week-long awareness campaign, has revealed what it calls a "devastating national crisis" marked by diagnosis delays and a severe mental health toll.
Waiting for a diagnosis Chronic pain is a common and complex condition characterised by persistent pain experienced on most days of the week, according to the Australian Institute of Health and Welfare. Approximately one in five Australians, or 3.6 million, live with chronic pain. However, Chronic Pain Australia believes the figure is higher. "That figure came from a study that was done about 15 years ago," Chronic Pain Australia chair Nicolette Ellis said.
"What we're predicting chronic pain is sitting at in [terms of] prevalence is about four million Australians in this day and age, and [this is] projected to go up to five million in 2050."
Of the almost 5,000 survey respondents, many had multiple conditions, including pain, joint pain and nerve pain, often experienced at the same time.
Over half (54 per cent) of respondents reported waiting more than two years for a diagnosis, and 44 per cent waited over three years. This has increased from 42 per cent waiting over three years in 2024, and 41 per cent in 2023.
Mental health impacts — and a 'pervasive' stigma Ellis said delayed diagnoses can contribute to the "vicious cycle" of chronic pain, including mental ill health. "For a lot of people, it takes away their identity, increases their mental health issues … and that's because of [what] pain can take away," she said. "If you're waiting for a diagnosis, typically you lose function. That might be reduced hours at work, or it might be leaving the workforce altogether."
The report revealed 74 per cent of respondents had experienced mental health impacts, with 87 per cent experiencing sleep disturbances.
Among other impacts was 63 and 59 per cent of respondents who experienced strain on family relationships and friendships. Stigma around chronic pain is "pervasive", according to the report, which found 74 per cent reported feeling ignored or dismissed. Ellis said this can come from health professionals along with friends, family, and community members. However, reported stigma from health professionals was higher than overall levels.
"Many people feel gaslit or stigmatised by health professionals — that this is all in their head and it's not a true condition," she said.
Calls for more complex care Despite the complex nature of chronic pain, the report found access to appropriate multidisciplinary and specialist care is falling short. Only 18 per cent of respondents received a referral to multidisciplinary pain management, and 30 per cent of those referred never secured an appointment. Ellis said access to multidisciplinary care is limited and dependent on location. "If you're in a metropolitan area, usually you can get into a tertiary or hospital-based pain clinic. But they have massive wait lists," she said.
"Access to that kind of care is very limited."
Chronic Pain Australia has been advocating for integrating multidisciplinary care programs into primary care settings. Ultimately, it wants to see chronic pain recognised as a condition in its own right — and made a national health priority. "Currently, we don't recognise pain as a condition in its own right; we recognise it as a symptom. What that means is that not only is chronic pain invisible to society, it's invisible in our health system data and in our policies," Ellis said. Ellis said recognising chronic pain in its own right would increase awareness of the condition, to guide adequate funding and resources. SBS News has contacted the federal health department for comment. It's understood the latest report will be presented to parliament later this week. For Stevenson, having access to early diagnosis and complex care can make an "extraordinary difference". "It means that someone who may otherwise be bedridden for weeks and weeks on end can actually participate in society, can maintain a healthy work-life balance, and can go about their days as a person living as pain free as possible, which surely we all deserve."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Australian
an hour ago
- The Australian
Spike in adverse event reports for ADHD medication Vyvanse
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' The TGA issued an alert about a typo on the Vyvanse label earlier this year. Picture: TGA 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Last year, 1.8m Vyvanse prescriptions were written in Australia, excluding Department of Veterans' Affairs patients, over-the-counter drugs, private prescriptions and public inpatient prescriptions. Picture: NewsWire / Martin Ollman Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said. Blair Jackson Reporter Blair's journalism career has taken him from Perth, to New Zealand, Queensland and now Melbourne. Blair Jackson

News.com.au
5 hours ago
- News.com.au
Spike in ADHD medication adverse event reports
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said.

News.com.au
6 hours ago
- News.com.au
Measles alert issued across NT airports, tourism hotspots
Northern Territory health authorities have issued a measles alert after a man travelled through multiple tourism hotspots before ending up in hospital in north Queensland. NT Health issued the alert on Saturday morning, warning anyone who was on tourism trips in the state, at restaurant in Kakadu National Park, or travelled through Darwin or Alice Springs Airports on specific dates in July to be alert for measles symptoms. These include a fever, sore eyes, a runny nose, a cough, and a blotchy red rash. 'Check your vaccination status,' an NT Health spokesperson said. 'Measles is highly contagious but preventable with two doses of a measles-containing vaccine.' Health authorities suspect the man who travelled while infectious acquired measles in Indonesia. 'The NT Centre for Disease Control is urging Territorians to be alert following confirmation of a measles case who travelled through Darwin and Alice Springs while infectious,' the alert reads. 'The individual, likely infected overseas, visited multiple public locations in the NT between July 17 and 23.' NT Health says the man was likely infectious when he went on an all-day tour with Ethical Adventures in Litchfield National Park on July 17. The next day, he left for an overnight tour with AAPT Kings Jabiru, and was at the Mercure Kakadu Crocodile Hotel in Jabiru from 6pm to 8pm on July 18. The measles alert does not account for his movements the next two days, but the next listed location is the Museum and Art Gallery of the Northern Territory, from 1pm to 3pm on July 20. It is believed the man then went to Darwin Airport at 3.30pm and flew to Alice Springs on Qantas flight QF1960, arriving at 7pm. On Wednesday, July 23, the man flew from Alice Springs to Cairns on Air North flight TL361. 'Anyone who attended these locations during these times should monitor for symptoms … Symptoms can take up to 18 days after exposure to develop,' the alert said. 'The vaccine is safe and effective, and available from your GP, local health centre, Aboriginal health clinic, and vaccinating pharmacies.'